Avience Biomedicals made a spectacular debut on the NSE SME platform, with its shares rocketing 90% on listing day. The Rs 30.24 crore IPO, which was oversubscribed a staggering 385 times, saw strong demand across all investor categories. The company, a manufacturer of molecular diagnostic solutions, plans to use the IPO proceeds to expand its manufacturing capabilities and meet working capital needs.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.